The current study aimed to analyze the pooled effects and adverse events of brigatinib in patients with <i>ALK</i>-positive NSCLC.<h4>Methods</h4>The pooled estimates and 95% confidence intervals (CI) were calculated with DerSimonian-Laird method and the random effect model.<h4>Results</h4>The pooled objective response rate (ORR) and disease control rate (DCR) of brigatinib were 64% (95% CI 45%-83%) and 88% (95% CI 80%-96%), respectively. The gene discussed is ALK; the disease is non-small cell lung carcinoma.